Does Geisinger Health Plan Cover Propecia?

What Is Propecia and How Does It Work?

Propecia is the brand-name tablet containing finasteride 1 mg, approved by the FDA in 1997 for androgenetic alopecia in men. Finasteride inhibits type II 5-alpha reductase, cutting serum dihydrotestosterone (DHT) by roughly 65 to 70% within 24 hours of the first dose. [1]

The Two Approved Doses

The 1 mg dose targets scalp DHT to slow hair follicle miniaturization. The 5 mg dose, sold as Proscar, is FDA-approved for BPH and also prescribed off-label by some urologists at the lower 1 mg dose for hair loss. The FDA's finasteride label distinguishes these two indications clearly, and insurers treat them very differently at the claims level. [2]

Clinical Evidence Behind the Drug

A 48-week randomized controlled trial published in the Journal of the American Academy of Dermatology found that finasteride 1 mg increased hair count by a mean of 107 hairs per 1-inch-diameter circle versus a loss of 50 hairs in the placebo group (P<0.001). [3] That same trial enrolled 1,553 men aged 18 to 41, making it the largest controlled study of finasteride for hair loss at the time of publication.

A 2019 Cochrane review of male androgenetic alopecia treatments confirmed that finasteride 1 mg is more effective than placebo at both 12 and 24 months for increasing hair count and patient self-assessment scores. [4]

How Geisinger Health Plan Organizes Its Drug Formulary

Geisinger Health Plan uses a tiered formulary structure common to most Blue-licensed and regional insurer models. Drugs are placed on Tier 1 (lowest cost-share, usually preferred generics), Tier 2 (non-preferred generics or low-cost brands), Tier 3 (preferred brands), or Tier 4 and above (specialty or non-preferred brands).

Where Finasteride Typically Lands

Generic finasteride 5 mg for BPH has historically appeared on Tier 1 or Tier 2 on Geisinger commercial plans because it is a widely available generic with multiple manufacturers. Generic finasteride 1 mg occupies a similar tier on plans that allow it at all. The brand Propecia (1 mg) sits higher, often Tier 3 or Tier 4, meaning a 30-day supply could cost $50, $100 or more depending on your deductible phase.

The Geisinger Health Plan drug formulary is updated quarterly. Checking the online formulary tool or calling 800-498-9731 (member services) gives you real-time tier placement.

The Cosmetic Exclusion Problem

Most Geisinger commercial plan documents contain a cosmetic exclusion clause. Androgenetic alopecia, while a recognized medical diagnosis (ICD-10-CM L64.9), is classified by many payers as a cosmetic condition when treated pharmacologically for hair regrowth rather than disease management. [5] That exclusion is the primary reason finasteride 1 mg claims get denied even when the drug appears on the formulary.

BPH does not carry a cosmetic exclusion. If your prescribing physician codes the visit as N40.1 (BPH with lower urinary tract symptoms), finasteride 5 mg is almost always covered under the medical benefit or standard pharmacy benefit without cosmetic-exclusion interference.

Prior Authorization: When Is It Required?

Prior authorization (PA) is a pre-approval step that Geisinger's pharmacy benefit manager may require before covering certain drugs. For finasteride, PA requirements depend on the plan type.

Commercial and Exchange Plans

On most Geisinger commercial plans, generic finasteride 5 mg for BPH does not require PA when the prescriber includes a valid BPH diagnosis. Finasteride 1 mg for hair loss may trigger PA or an automatic denial depending on the specific plan document language. The American Academy of Dermatology guidelines on androgenetic alopecia recommend finasteride as first-line pharmacologic therapy, a point your dermatologist can cite in a PA letter. [6]

Medicare Advantage Plans

Geisinger offers Medicare Advantage products including Geisinger Gold. CMS rules do not mandate coverage of drugs used primarily for cosmetic purposes, and CMS Part D guidance explicitly excludes drugs used for hair growth from the standard Part D benefit. [7] That means finasteride 1 mg for alopecia is very unlikely to be covered under any Geisinger Gold plan, and members typically pay out-of-pocket.

Medicaid Managed Care

Pennsylvania Medicaid (MA) managed through Geisinger Health Plan follows the Pennsylvania Department of Human Services preferred drug list. Generic finasteride 5 mg for BPH is generally listed as preferred. Finasteride 1 mg for hair loss is not listed as a covered use. The Pennsylvania DHS preferred drug list is updated monthly.

Step-by-Step: How to Verify Your Coverage Before Filling

Getting a straight answer from an insurer requires asking the right questions in the right order.

Step 1: Pull Your Summary of Benefits and Coverage

Your Summary of Benefits and Coverage (SBC) document, required under the ACA Section 2715, lists exclusions in plain language. [8] Search the PDF for "cosmetic" and "hair" to find exact exclusion language before calling anyone.

Step 2: Run a Formulary Check

Go to the Geisinger member portal or use the CMS formulary finder if you have Medicare Advantage. Enter NDC or drug name, select your plan, and record the tier and any PA flag.

Step 3: Call Member Services

Call the number on your card. Ask these four questions exactly:

1. Is finasteride [1 mg / 5 mg] covered under my plan?
2. What ICD-10 codes are accepted for coverage without PA?
3. Does a cosmetic exclusion apply to this drug for hair loss?
4. What is the formulary exception process if coverage is denied?

Document the representative's name, the date, and the reference number for the call.

Step 4: Get the Prescriber to Submit a Letter of Medical Necessity

A letter from your dermatologist or primary care physician stating that hair loss is causing documented psychological distress, citing the DLQI (Dermatology Life Quality Index) score if possible, can shift a cosmetic denial toward medical necessity. [9] A DLQI score above 10 indicates a very large effect on quality of life and is difficult for a plan to ignore in an internal appeal.

What Finasteride Actually Costs Without Coverage

Generic finasteride is one of the least expensive prescription drugs in the United States. GoodRx pricing at major retail chains runs approximately:

| Supply | Finasteride 1 mg | Finasteride 5 mg | |--------|-----------------|-----------------| | 30 tablets | $10, $18 | $8, $15 | | 90 tablets | $25, $40 | $20, $35 |

The FDA's drug shortage database shows finasteride is not in shortage as of early 2025, meaning multiple generic manufacturers compete, keeping prices low. [10]

For many patients on Geisinger commercial plans with deductibles above $1,000, paying cash for generic finasteride may be cheaper than applying the drug toward the deductible, particularly if using a pharmacy discount card.

Appealing a Denial: Your Rights and Strategy

Insurance denials are not final. Federal law under ERISA Section 503 and the ACA guarantees at least one internal appeal and one external review for most employer-sponsored plans. [11]

Internal Appeal

You have 180 days from the denial notice to file an internal appeal. The appeal letter should include:

• The specific denial reason from the Explanation of Benefits (EOB)
• A letter of medical necessity from your prescriber citing relevant clinical guidelines
• Published evidence such as the AAD guidelines or the Cochrane review cited above [4]
• Your DLQI score or documented psychiatric comorbidity if applicable

The Kaiser Family Foundation 2023 Employer Health Benefits Survey found that 39 to 59% of internal appeals result in reversal when supported by clinical documentation. [12]

External Review

If the internal appeal fails, you may request an external review by an Independent Review Organization (IRO) within four months. Pennsylvania IROs are accredited through the state Insurance Department. The external reviewer must apply medical evidence standards, not just plan language, which gives a well-documented hair-loss claim a meaningful second chance.

The BPH Workaround: Is It Appropriate?

Some physicians prescribe finasteride 5 mg for patients who have both BPH symptoms and hair loss, which may result in coverage. Prescribers can legitimately document both diagnoses. Pill-splitting finasteride 5 mg to approximate four 1.25 mg doses is practiced widely, though this is off-label and the FDA label does not endorse splitting. [2] Patients should discuss the appropriateness of this approach directly with their physician. A physician who documents only BPH to obtain coverage for hair loss without genuine BPH creates an ethical and legal risk that neither the patient nor the prescriber should accept.

Side Effects and Safety: What Geisinger's Medical Reviewers Consider

When reviewing PA requests or appeals, Geisinger's clinical pharmacists apply criteria that include medical necessity and safety appropriateness. Finasteride's safety profile is a factor.

Post-Finasteride Syndrome

The FDA updated finasteride's label in 2012 to include persistent sexual side effects including libido changes and erectile dysfunction that may continue after drug discontinuation. [2] This is documented in the literature, and a 2011 study in the Journal of Sexual Medicine found that 20 of 54 men with finasteride-associated sexual dysfunction reported persistence for at least three months after stopping the drug. [13]

Prostate Cancer Risk

The Prostate Cancer Prevention Trial (PCPT), a randomized trial of 18,882 men, found that finasteride 5 mg reduced overall prostate cancer incidence by 24.8% but was associated with a higher proportion of high-grade tumors in those who did develop cancer (P<0.001). [14] This finding has not changed the drug's approval status but is part of the risk discussion every prescriber should conduct.

Pregnancy Exposure

The FDA Pregnancy Category X designation for finasteride means it is contraindicated in women who are or may become pregnant due to the risk of genital abnormality in male fetuses. [2] This is particularly relevant for Geisinger's clinical review teams when evaluating off-label requests from female patients, where coverage for female-pattern hair loss would be even less likely than in men.

Alternatives Covered by Geisinger Health Plan

If finasteride for hair loss is denied, other options carry different coverage profiles.

Minoxidil

Topical minoxidil 2% and 5% solution and foam are available over the counter. No prescription is needed, so insurance coverage is not applicable. Oral minoxidil (0.625 to 2.5 mg daily) is prescribed off-label for hair loss and may be covered under a general formulary listing for hypertension, where minoxidil 2.5 mg tablets are commonly Tier 1 generics. [15]

Dutasteride

Dutasteride inhibits both type I and type II 5-alpha reductase, producing deeper DHT suppression than finasteride. It is FDA-approved for BPH only, but a 2021 meta-analysis in the Journal of the American Academy of Dermatology found dutasteride 0.5 mg superior to finasteride 1 mg for hair count at 24 weeks. [16] Generic dutasteride is often Tier 1 or Tier 2 on Geisinger formularies for BPH; the same cosmetic-exclusion problem applies for hair loss.

Ketoconazole Shampoo

Ketoconazole 2% shampoo has shown modest benefit in small trials as an adjunct to finasteride. [17] It is prescription-only at 2% and may be covered under Geisinger pharmacy benefits as an antifungal, making the diagnosis code (tinea capitis or seborrheic dermatitis) the key driver.

Platelet-Rich Plasma (PRP)

PRP injections for hair loss are almost universally excluded by Geisinger Health Plan and other insurers as experimental and cosmetic. A 2019 systematic review in Dermatologic Surgery found PRP improved hair density but noted that study heterogeneity and small sample sizes limit the evidence base. [18]

Special Populations: Women and Finasteride

Finasteride is not FDA-approved for women, but off-label use in postmenopausal women with female-pattern hair loss exists. Coverage for off-label use faces a double barrier: the cosmetic exclusion and the off-label status. The Endocrine Society's clinical practice guideline on female pattern hair loss does not include finasteride as a recommended treatment, which removes a key clinical authority document that might support a PA appeal. [19]

Telehealth and Compounded Finasteride

Telehealth platforms that prescribe compounded finasteride (sometimes combined with minoxidil in a topical formula) operate outside the standard insurance framework. Compounded drugs are not FDA-approved finished products and are not covered by Geisinger Health Plan or any other major insurer's pharmacy benefit. The FDA's guidance on compounding makes clear that compounded products cannot be sold as substitutes for commercially available FDA-approved drugs. [20] Patients pay cash, typically $30, $80 per month depending on formulation.